

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**利君國際醫藥(控股)有限公司**  
Lijun International Pharmaceutical (Holding) Co., Ltd.

*(Incorporated in the Cayman Islands with limited liability)*  
(Stock Code: 2005)

**TRADING HALT**

At the request of Lijun International Pharmaceutical (Holding) Co., Ltd. (the “**Company**”), trading in the shares of the Company on The Stock Exchange of Hong Kong Limited has been halted with effect from 9:30 a.m. on 30 October 2014 pending the release of an announcement in relation to clarification of information in the announcement issued by the Company dated 29 October 2014 relating to the turnover and gross profit information for the nine months ended 30 September 2014.

By Order of the Board  
Chan Ka Kit  
*Company Secretary*

Hong Kong, 30 October 2014

*As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Wang Xianjun and Mr. Duan Wei as executive Directors, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.*

*All the Directors jointly and severally accept full responsibility for the accuracy of information contained in this announcement and confirm, having made all reasonable inquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statement in this announcement misleading.*